Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A Phase I, Multi-center, Open Label Dose Escalation Study of LDK378, Administered Orally in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)
ceritinib
CLDK378X2101
NCT01283516
Tumors Characterized by Genetic Abnormalities of ALK
Phase 1/2
 
July 2016

Powered by ideaPoint, Inc.